MolGen Acquires Synchron

MolGen announced last Wednesday that it has acquired Dutch automation company Synchron Instrumenten BV, also known as Synchron Lab Automation.

MolGen Acquires Synchron

Image Credit: MolGen  

With this acquisition, MolGen will expand its existing portfolio and its ability to build high-end automation solutions for DNA/RNA purification, library preparation and NGS setup to support MolGen’s reagent business. The custom liquid handling platforms and rapid prototyping capabilities of Synchron will be used to further expand MolGen’s automation portfolio.

This acquisition will enable MolGen to more efficiently build automation solutions, to enable our customers globally; to meet the challenges in terms of the increasing demand of sample throughput and cost efficiency.” 

Niels Kruize, CEO, MolGen

MolGen and Synchron have already co-developed several automated solutions in recent years, ranging from systems for sample transfer from capped sample tubes to microtitre plates, to a platform for ultra high throughput DNA/RNA purification, called the DNA Factory. This system provides serial automation that enables laboratories to scale up DNA/RNA purification, PCR setup and library preparation for NGS applications.

Derk Wilten will continue as Managing Director of Synchron and all other contacts at Synchron remain unchanged.

Synchron will be enabled to grow and reach more customers globally, via MolGens commercial, application and service team. Combining our hard- and software solutions with MolGen’s reagents will enable us to offer novel solutions and entire workflows that are in strong demand in high throughput genomics labs,” says Derk Wilten, Managing Director of Synchron.



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    MolGen. (2023, April 28). MolGen Acquires Synchron. AZoLifeSciences. Retrieved on July 21, 2024 from

  • MLA

    MolGen. "MolGen Acquires Synchron". AZoLifeSciences. 21 July 2024. <>.

  • Chicago

    MolGen. "MolGen Acquires Synchron". AZoLifeSciences. (accessed July 21, 2024).

  • Harvard

    MolGen. 2023. MolGen Acquires Synchron. AZoLifeSciences, viewed 21 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.